Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cleary

Showing results (411-420 of 445) with videos related to

Pageof 45
Sort By:
Nature Communications|February 6, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancersJames J Harding, Sarina A Piha-Paul, Ronak H Shah, et al.
JNCI Cancer Spectrum|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical TrialsNadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.
JAMA Oncology|September 23, 2021
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy TrialAndrew X Zhu, Teresa Macarulla, Milind M Javle, et al.
The New England Journal of Medicine|February 5, 2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive CancerAlison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsHarshabad Singh, Yvonne Y Li, Liam F Spurr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2023
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Rachel B Keller, Kevin S Kapner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2022
Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic CancerAndressa Dias Costa, Sara A Väyrynen, Akhil Chawla, et al.
Nature Communications|January 26, 2018
C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca<sup>2+</sup>-permeable AMPA receptor-mediated excitotoxicityBhuvaneish T Selvaraj, Matthew R Livesey, Chen Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Biorxiv : the Preprint Server for Biology|July 19, 2024
Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targetsVindhya Vijay, Negin Karisani, Lei Shi, et al.
Pageof 45

Showing results (411-420 of 445) with videos related to

Sort By:
Pageof 45
Nature Communications|February 6, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancersJames J Harding, Sarina A Piha-Paul, Ronak H Shah, et al.
JNCI Cancer Spectrum|May 23, 2022
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical TrialsNadine J McCleary, William S Harmsen, Ellana Haakenstad, et al.
JAMA Oncology|September 23, 2021
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy TrialAndrew X Zhu, Teresa Macarulla, Milind M Javle, et al.
The New England Journal of Medicine|February 5, 2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion-Positive CancerAlison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsHarshabad Singh, Yvonne Y Li, Liam F Spurr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2023
Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic CancerHarshabad Singh, Rachel B Keller, Kevin S Kapner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2022
Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic CancerAndressa Dias Costa, Sara A Väyrynen, Akhil Chawla, et al.
Nature Communications|January 26, 2018
C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca<sup>2+</sup>-permeable AMPA receptor-mediated excitotoxicityBhuvaneish T Selvaraj, Matthew R Livesey, Chen Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid TumorsRyan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Biorxiv : the Preprint Server for Biology|July 19, 2024
Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targetsVindhya Vijay, Negin Karisani, Lei Shi, et al.
Pageof 45